dextropropoxyphene has been researched along with debrisoquin in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Bertilsson, L; Sanz, EJ | 1 |
| Armstrong, M; Astbury, C; Beyeler, C; Bird, HA; Daly, AK; Idle, JR | 1 |
4 other study(ies) available for dextropropoxyphene and debrisoquin
| Article | Year |
|---|---|
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
d-Propoxyphene is a potent inhibitor of debrisoquine, but not S-mephenytoin 4-hydroxylation in vivo.
Topics: Administration, Oral; Adolescent; Adult; Debrisoquin; Dextropropoxyphene; Female; Humans; Hydantoins; Hydroxylation; Isomerism; Isoquinolines; Male; Mephenytoin; Polymorphism, Genetic | 1990 |
Phenotype/genotype relationships for the cytochrome P450 enzyme CYP2D6 in rheumatoid arthritis: influence of drug therapy and disease activity.
Topics: Adult; Aged; Alleles; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Debrisoquin; Dextropropoxyphene; Disease Susceptibility; Female; Genotype; Humans; Hydroxylation; Male; Middle Aged; Mixed Function Oxygenases; Phenotype; Reference Values | 1994 |